Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

被引：8
|
作者：
Wainberg, Zev A.
Shitara, Kohei
Van Cutsem, Eric
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol Cheol
Lee, Jeeyun
Castro-Salguero, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Goekkurt, Eray
Satake, Hironaga
Chao, Joseph
Kher, Uma
Shah, Sukrut
Bhagia, Pooja
Tabernero, Josep
机构：
[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Univ Hosp Gasthuisberg, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
[5] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[6] Inst Oncol, Warsaw, Poland
[7] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[8] Latvian Oncol Ctr Rakus Gailezers, Riga, Latvia
[9] Pontificia Univ Catolica Chile, Santiago, Chile
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Samsung Med Ctr, Seoul, South Korea
[12] Los Angeles Med Grp, Guatemala City, Guatemala
[13] Christie Hosp NHS Trust, Manchester, Lancs, England
[14] Univ Sao Paolo, Inst Canc Sao Paolo, Sao Paulo, Brazil
[15] SPb SBHI Clin Oncol Dispensary, St Petersburg, Russia
[16] Hematol Oncol Practice Eppendorf, Hamburg, Germany
[17] Univ Canc Ctr Hamburg, Hamburg, Germany
[18] Gen Hosp, Kobe City Med Ctr, Kobe, Hyogo, Japan
[19] City Hope Comprehens Canc Ctr, Duarte, CA USA
[20] Merck & Co Inc, Kenilworth, NJ USA
[21] Hebron Univ Hosp HUVH, Barcelona, Spain
[22] UVic UCC, IOB Quiron, Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
    Mehnert, J. M.
    Rugo, H. S.
    O'Neil, B. H.
    Santoro, A.
    Schellens, J. H. M.
    Cohen, R. B.
    Doi, T.
    Ott, P. A.
    Pishvaian, M. J.
    Puzanov, I.
    Aung, K. L.
    Hsu, C.
    Le Tourneau, C.
    Soria, J-C.
    Elez, E.
    Tamura, K.
    Gould, M.
    Zhao, G.
    Stein, K.
    Piha-Paul, S. A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [32] Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
    Janjigian, Y.
    Kawazoe, A.
    Weber, P.
    Luo, S.
    Lonardi, S.
    Kolesnik, O.
    Barajas, O.
    Bai, Y.
    Shen, L.
    Tang, Y.
    Wyrwicz, L.
    Shitara, K.
    Qin, S.
    Van Cutsem, E.
    Tabernero, J.
    Li, L.
    Shih, C.
    Bhagia, P.
    Chung, H.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S227 - S227
  • [33] KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer
    Daniel, Catenacci, V
    Zev, Wainberg
    Charles, Fuchs S.
    Marcelo, Garrido
    Bang Yung-Jue
    Kei, Muro
    Mary, Savage
    Wang Jiangdian
    Minori, Koshiji
    Rita, Dalal P.
    Yoon-Koo, Kang
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [34] KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC
    Ren, Shengxiang
    Feng, Jifeng
    Ma, Shenglin
    Chen, HuaJun
    Ma, Zhiyong
    Huang, Cheng
    Zhang, Li
    He, Jianxing
    Wang, Changli
    Zhou, Jianying
    Danchaivijtr, Pongwut
    Wang, Chin-Chou
    Vynnychenko, Ihor
    Wang, Kai
    Orlandi, Francisco
    Sriuranpong, Virote
    Li, Ben
    Ge, Jun
    Dang, Thao
    Zhou, Caicun
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) : 623 - 634
  • [35] Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective
    Li, Wei
    Wan, Li
    Zhang, Jiangyan
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (06) : 293 - 301
  • [36] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress
    Kato, K.
    Shah, M.
    Enzinger, P.
    Bennouna, J.
    Shen, L.
    Adenis, A.
    Sun, J.
    Cho, B.
    Ozguroglu, M.
    Kojima, K.
    Kostorov, V.
    Hierro, C.
    Zhu, Y.
    Shah, S.
    Bhagia, P.
    Doi, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [38] Pembrolizumab in Paediatric Patients with Advanced Melanoma or A PD-L1-Positive (PD-L1+) Advanced, Relapsed, or Refractory Solid Tumour or Lymphoma: Phase 1/2 Keynote-051 Study
    Geoerger, B.
    Fox, E.
    Pappo, A.
    Yalon-Oren, M.
    Marshall, V.
    Vezina, C.
    Pathiraja, K.
    Diede, S. J.
    Ebbinghaus, S.
    Park, J. R.
    [J]. PEDIATRIC BLOOD & CANCER, 2016, 63 : S195 - S195
  • [39] JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).
    Moehler, Markus H.
    Ryu, Min-Hee
    Lee, Keun-Wook
    Coskun, Hasan Senol
    Wong, Rachel
    Ozguroglu, Mustafa
    Chung, Hyun-Choel
    Poltoratsky, Artem
    Tsuji, Akihito
    Yen, Chia-Jui
    Muntean, Alina
    le Sourd, Samuel
    Vaccaro, Gina M.
    Taieb, Julien
    Boku, Narikazu
    Sharma, Maitreyi
    Xiong, Huiling
    Conti, Ilaria
    Bang, Yung-Jue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1-positive advanced, relapsed or refractory solid tumor or lymphoma.
    Geoerger, Birgit
    Kang, Hyoung Jin
    Yalon-Oren, Michal
    Marshall, Lynley V.
    Vezina, Catherine
    Pappo, Alberto S.
    Laetsch, Theodore Willis
    Petrilli, Antonio Sergio
    Ebinger, Martin
    Toporski, Jacek
    Glade-Bender, Julia
    Nicholls, Wayne
    Fox, Elizabeth
    DuBois, Steven G.
    Macy, Margaret
    Cohn, Susan Lerner
    Pathiraja, Kumudu
    Diede, Scott J.
    Ebbinghaus, Scot
    Pinto, Navin R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345